Non-viral drug delivery systems have gained immense popularity in recent years owing to their advantages over viral delivery methods including low immunogenicity, larger transgene capacity and ease of production. Non-viral techniques involve encapsulating drugs into nanoparticles, liposomes or conjugating them to targeting moieties and are generally considered safer than viral vectors.
The Non-Viral Drug Delivery Systems Market is estimated to be valued at US$ 8.1 Bn in 2024 and is expected to exhibit a CAGR of 13% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the non-viral drug delivery systems market are Arcturus Therapeutics, Bio-Path Holdings, CureVac, Entos Pharmaceuticals, eTheRNA Immunotherapies. The companies are investing heavily in R&D to develop novel non-viral vectors with higher efficiency and safety. The growing demand for targeted drug delivery systems is a major factor driving the non-viral drug delivery systems market. Non-invasive therapeutic delivery through oral, transdermal and inhalation routes has gained prominence. Technological advancements like lipid nanoparticles, polymeric nanoparticles and conjugation with cell-penetrating peptides have increased the delivery of macromolecules.
Market Trends
One of the major trends in the non-viral drug delivery systems market is the rising focus on gene therapy. Non-viral gene delivery methods offer less immunogenic and inflammatory responses making them safer for repeated administration. mRNA-based therapies and applications in cancer immunotherapy are emerging as lucrative opportunities. Another key trend is the development of stimuli-responsive delivery systems that are designed to release drug payloads in response to specific biochemical cues like pH, redox potential or enzymatic activity at the site of action.
Market Opportunities
Targeted delivery to tumors using actively/passively targeted nanoparticles presents a huge opportunity. The application of nanotechnology has allowed efficient delivery of anti-cancer drugs, imaging agents and nucleic acids selectively to tumor tissues. Oligonucleotide therapeutics also offer lucrative opportunities given the advances in mRNA vaccines. Non-invasive delivery through pulmonary route for treatment of lung cancers and respiratory diseases is an emerging area of focus.
Impact Of COVID-19 On Non-Viral Drug Delivery Systems Market Growth
The COVID-19 pandemic has significantly impacted the non-viral drug delivery systems market. During the initial phases of the pandemic, most non-essential research was put on hold or delayed, impacting the development of new drug delivery technologies. Companies focused their efforts on developing COVID-19 vaccines and therapeutics to address the urgent medical need. This diverted resources away from other drug delivery applications.
However, as the pandemic progressed, companies recognized the long-term market potential for non-viral delivery platforms to address future pandemics and other diseases. Nanoparticle-based delivery systems can effectively transport mRNA, DNA and protein therapeutics into cells, making them well-suited for developing new classes of antiviral drugs and vaccines. Several companies utilized their non-viral platforms to design COVID-19 vaccines and therapies during clinical trials.
Going forward, governments and healthcare agencies are expected to prioritize research into development capabilities for rapid responses to health emergencies. Non-viral delivery technologies can play a major role here through their ability to package different types of biologics and enable faster discovery processes compared to viral vectors. Companies are also advancing formulations tuned for stability at varying temperatures and extended shelf-life to address logistical challenges in vaccine distribution globally.
North America Dominates Non-Viral Drug Delivery Systems Market
The North America region currently dominates the Non-Viral Drug Delivery Systems Market in terms of value. This is due to presence of established pharmaceutical and biotechnology companies engaged in development and commercialization of delivery platforms for various biologics. Large companies have made significant investments setting up research centers focused on non-viral technologies.
Government funding for innovation is also strong through the National Institute of Health and Department of Defense programs. Academic research is rapidly advancing new formulations and delivery routes. The U.S. and Canada also have a well-developed regulatory system to approve new drug-device combination products incorporating non-viral carriers. High healthcare spends per capita contribute to faster market uptake of advanced therapeutics enabled by these platforms.
Asia Pacific Emerging As Fastest Growing Region
Going forward, the Asia Pacific region is expected to offer the fastest market growth opportunities for non-viral drug delivery systems. This is attributable to rising chronic disease prevalence in highly populated countries like China and India. Governments are investing significantly to build local R&D capabilities through initiatives such as the Made in China 2025 policy.
Countries like South Korea and Japan also have large biotechnology industries focusing on formulations. At the same time, reduced manufacturing and labor costs are attracting global pharmaceutical companies to outsource production to Asia Pacific contract development and manufacturing organizations. This will help expand regional production capacities for various non-viral technologies.
Get more insights on this topic: https://www.ukwebwire.com/non-viral-drug-delivery-systems-market-are-estimated-to-witness-high-growth-owing-to-advancements-in-nanotechnology/
About Author:
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement. (LinkedIn - https://www.linkedin.com/in/priya-pandey-8417a8173/)
What Are The Key Data Covered In This Non-Viral Drug Delivery Systems Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Non-Viral Drug Delivery Systems Market's growth between 2024 and 2031.
:- Accurate calculation of the size of the Non-Viral Drug Delivery Systems Market and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Non-Viral Drug Delivery Systems Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market's competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Non-Viral Drug Delivery Systems Market vendors
FAQ’s
Q.1 What are the main factors influencing the Non-Viral Drug Delivery Systems Market?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top Non-Viral Drug Delivery Systems Market companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Non-Viral Drug Delivery Systems Market’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Comments
0 comment